Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310136 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL29260056 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL21069737 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL22609548 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL31085811 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL29267051 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL14497257 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL24480809 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL24480657 | 0.92 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL21876995 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260035356-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4444717-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | University of Florida Research Foundation, Incorporated (US) | 2024-10-16 | — | — | EP | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-2623491-A2 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-10 | — | — | US | disclosed |
| US-7858622-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| WO-2010115491-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7579341-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| WO-1999020606-A2 | PIPERIDINES AND PIPERAZINES AS PLATELET AGGREGATION INHIBITORS | J. URIACH & CIA. S.A. (ES) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | EGFR, BLK, CSNK1A1L | SMN1; SMN2 4694/4885NPC1 1807/4885RAB9A 1068/4885 |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | SMN1; SMN2 1742/4885NPC1 2415/4885RAB9A 2152/4885 |
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | SMN1; SMN2 4312/4885NPC1 1278/4885RAB9A 2103/4885 |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | SMN1; SMN2 1593/4885NPC1 4748/4885RAB9A 3951/4885 |
| US-20260035356-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | TYK2, CRBN, CSNK2A3 | SMN1; SMN2 2508/4885NPC1 4601/4885RAB9A 3454/4885 |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | SMN1; SMN2 4032/4885NPC1 3798/4885RAB9A 1773/4885 |
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | SMN1; SMN2 2737/4885NPC1 4506/4885RAB9A 4197/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | SMN1; SMN2 2737/4885NPC1 4506/4885RAB9A 4197/4885 |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SMN1; SMN2 4312/4885NPC1 1278/4885RAB9A 2103/4885 |
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | SMN1; SMN2 4312/4885NPC1 1278/4885RAB9A 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.